Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01025349|
Recruitment Status : Completed
First Posted : December 3, 2009
Last Update Posted : December 3, 2009
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Breast Cancer||Drug: Bevacizumab, docetaxel, cisplatin||Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Retrospective Analysis of Salvage Therapy With Bevacizumab Plus Docetaxel and Cisplatin for Taiwanese Metastatic Breast Cancer|
|Study Start Date :||January 2005|
|Actual Primary Completion Date :||September 2009|
|Actual Study Completion Date :||September 2009|
Experimental: metastatic breast cancer
Patients with histological or cytological proven metastatic breast cancer were recruited. The previous hormonal therapy for metastatic breast cancer or cytotoxic therapy was allowed. The Her2/Neu over-expressive status should be negative. Patients with brain metastasis are excluded.
Drug: Bevacizumab, docetaxel, cisplatin
Bevacizumab 8 mg/kg(over 60 minutes) on first day of first cycle, followed by 5 mg/kg on first day of the rest cycles, repeat every 2 weeks.
docetaxel 45 mg/m2(over 60 minutes) on day 1 of each cycle, repeat every 2 weeks.
cisplatin 50 mg/m2(over 4 hours) on day 1 of each cycle, repeat every 2 weeks.
- Response Rate [ Time Frame: every 3 months ]
- Time to Progression(TTP), Progression free survival, overall survival, safety, Quality of Life [ Time Frame: every 3 months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01025349
|Taipei Medical University Hospital|
|Taipei, Taiwan, 110|
|Principal Investigator:||Cheng-Jeng Tai, M.D.||Section of Hematology-Oncology, Department of Medicine, Taipei Medical University Hospital|